Investor Clueso Subsribers,
We LOVED the AH news on HBRM yesterday! HBRM: Successfully secured direct consumer points-of-sale for its flagship product, AcnEase®.
The stock is trading very nicely with steady accumulation. With a relatively small float for the price, we believe HBRM has tremendous potential. Volume is always key in trading any stock and HBRM is definately attracting significant volume these days.
HBRM Share Structure:
May 7th, 2010
Herborium Group Commences AcnEase(R) Retail Sales
AcnEase(R) Now Available in New York Dermatology Clinics
Jun 2, 2010 3:00:00 PM
Herborium Group, Inc., (HBRM), a Botanical Therapeutics? company, today announced it has now successfully secured direct consumer points-of-sale for its flagship product, AcnEase®, with a recognized group of New York dermatological clinics.
"Acceptance of AcnEase by board certified dermatologist to be sold in the clinics is a major third-party validation of the therapeutic value of our product, and is an important cornerstone in building the AcnEase® brand," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer.
AcnEase® is a proprietary, all herbal, systemically acting botanical therapeutic targeting acne symptom in both females and males of all ages, and has been proven safe and effective through clinical testing. Test results have demonstrated that in adolescent acne, approximately 95% of patients responded positively to AcnEase. In individuals above age 31, the level of effectiveness was 80%. The overall positive response rate to AcnEase was 91%. After more than five years of online sales, Herborium has consistently registered over 95% consumer satisfaction rating (www.acnease.com
Dr. Olszewski continued, "Expanding beyond e-commerce (internet sales) to direct consumer points-of-sale is an important milestone in our overall plan to increase AcnEase sales and brand recognition and grow market share within the US 3.5 billion over the counter medicated skin care market
"With the current surge in sales of over-the-counter nutritional and health supplements, combined with Hoffmann-La Roche Inc.'s announcement to discontinue marketing of its leading treatment for severe acne, Accutane® (isotretinoin), and Herborium's AcnEase product's demonstrated and documented over five year history of safe and effective acne treatment, I firmly believe we have the right product, at the right time, for over 50 million acne sufferers in the USA.
"Having successfully launched our direct-to-consumer sales strategy with AcnEase in the US market , we intend to replicate this strategy to the extent justified "by market conditions" in International markets, while we prepare our next product sales initiative to access the US cosmeceutical market expected to potentially reach over $16 billion by 2010.
"Herborium is committed to continue developing a global brand with a strong international distribution network, and the acceptance of AcnEase by the dermatological community is a key development in both product branding and sales growth strategies," Dr. Olszewski concluded.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases,
Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events.
Dr. Agnes P. Olszewski
President & CEO
(201) 647-3757 (201) 647-3757